anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a biomarker for renal cell carcinoma and application thereof, and relates to the technical field of biological medicines. The biomarker is cyclic RNAcirc0003856, the nucleotide full sequence of the biomarker is shown as SEQ ID NO.1, and the cyclic sequence of the biomarker is shown as SEQ ID NO. 2. The invention also provides application of the reagent for reducing the expression level of the cyclic RNAcirc0003856 in preparing a medicament for treating renal cell carcinoma. The invention discovers that the annular RNAcirc0003856 can be used as a biomarker of the renal cell carcinoma, and the predictive value of the renal cell carcinoma is analyzed by using the working characteristic curve of the subject, so that the predictive value of the renal cell carcinoma is higher. The invention also discovers that the expression quantity of the annular RNAcirc0003856 is reduced, so that the cell activity of the kidney cancer cells can be obviously inhibited, the apoptosis of the kidney cancer cells is promoted, and the migration and invasion capacity of the kidney cancer cells are inhibited.
The invention relates to the technical field of medicine. Rheumatoid arthritis (RA) is one of the most important diseases which are harmful to human health at present, and the formidable task and problem to be solved in the global medicine world is to seek high-efficiency and low-toxicity medicaments for preventing and treating the RA. The invention provides negundo chastetree fruit extract. A method for preparing the negundo chastetree fruit extract comprises the following steps of: performing hot extraction on negundo chastetree fruit by using hydrous ethanol, concentrating extracting solution, loading to macroporous adsorbent resin, eluting by using the hydrous ethanol, concentrating eluent and drying to obtain the negundo chastetree fruit extract. Pharmacodynamic study indicates that the negundo chastetree fruit extract can be used for preparing medicaments or food for resisting the rheumatoid arthritis. The negundo chastetree fruit extract is a new source for seeking the medicaments for resisting the rheumatoid arthritis.
The invention provides a polypeptide-Fc fusion protein and a preparation method and application thereof. The polypeptide-Fc fusion protein comprises: the polypeptide is a polypeptide specifically targeting tumor cells and contains 5-30 amino acids, and the polypeptide and the Fc fragment are connected through a flexible peptide segment. The preparation method of the polypeptide-Fc fusion protein comprises the following steps: constructing an expression vector of the fusion protein, and expressing and purifying the fusion protein. The polypeptide-Fc fusion protein mediates cytotoxicity to kill tumor cells, not only retains the biological activity of the fusion protein, but also exerts the biological activity of the combination of the Fc segment and the Fc receptor. The polypeptide-Fc fusion protein constructed by the invention has small molecular weight, better tissue penetrability and better effect of reaching a tumor microenvironment more easily. The polypeptide is easy to screen, and a plurality of polypeptides can be used for fusion construction, so that the specificity and targeting property of the fusion protein to tumor cells are improved.
When using fluoxetine and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax®.

Adult — Administer fluoxetine in combination with oral olanzapine once daily in the evening, without regard to meals, generally beginning with 5 mg of oral olanzapine and 20 mg of fluoxetine. Make dosage adjustments, if indicated, according to efficacy and tolerability within dose ranges of fluoxetine 20 to 50 mg and oral olanzapine 5 to 12.5 mg. Antidepressant efficacy was demonstrated with olanzapine and fluoxetine in combination with a dose range of olanzapine 6 to 12 mg and fluoxetine 25 to 50 mg. Safety of co-administration of doses above 18 mg olanzapine with 75 mg fluoxetine has not been evaluated in clinical studies. Periodically re-examine the need for continue pharmacotherapy. 

Children and adolescents(10 to 17 years of age) — Administer olanzapine and fluoxetine combination once daily in the evening, generally beginning with 2.5 mg of olanzapine and 20 mg of fluoxetine. Make dosage adjustments, if indicated, according to efficacy and tolerability. Safety of co-administration of doses above 12 mg of olanzapine with 50 mg of fluoxetine has not been evaluated in pediatric clinical studies. Periodically re-examine the need for continued pharmacotherapy. 

Safety and efficacy of fluoxetine in combination with olanzapine was determined in clinical trials supporting approval of Symbyax® (fixed-dose combination of olanzapine and fluoxetine). Symbyax® is dosed between 3 mg/25 mg (olanzapine/fluoxetine) per day and 12 mg/50 mg (olanzapine/fluoxetine) per day. The following table demonstrates the appropriate individual component doses of fluoxetine and olanzapine versus Symbyax®. Adjust dosage, if indicated, with the individual components according to efficacy and tolerability.

1 Symbyax (olanzapine/fluoxetine HCL) is a fixed-dose combination of fluoxetine and olanzapine. 

Fluoxetine monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder.
Magnesium sulfate 20 mg/kg intravenous over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
Each subject be assessed at baseline and approximately 2 years later. At each time point, each participant will attend eight testing sessions (MRI scanning, two TMS-motor test visits, two TMS-prefrontal test visits, motor assessments, neuropsychological testing, and overnight sleep testing (polysomnography - PSG).
PURPOSE:To obtain the titled cosmetic, by laying a drying container in a frame or a mold, packing a liquid having fluidity obtained by dispersing powder cosmetic into a volatile solvent into the container, drying the liquid to solidify the powder cosmetic, arranging the multi-color solid cosmetic thus formed in a cosmetic container and pressing the cosmetic for finish. CONSTITUTION:A drying container is laid in a frame or a mold, a liquid having fluidity obtained by dispersing powder cosmetic into a volatile solvent (e.g. ethanol) is packed in to the drying container and the liquid is dried to solidify the powder cosmetic. In this case, the number of frames or molds prepared is the same number of the kinds of colors or one frame or mold is used by successively changing colors to give multi-color solid powder cosmetic. Then the solid powder cosmetic is cut into small pieces, a number of small pieces of different colors are arranged in a cosmetic container and lightly pressed to give the titled substance. EFFECT:The boundary line of color is clear and a complicated color pattern can be made. The number of processes is small and cosmetic has good utility because it becomes porous after drying.
FIELD: pharmaceuticals.SUBSTANCE: invention relates to the pharmaceutical industry, namely, to a method for quantifying the amount of flavonoids in walnut leaves. A method for quantifying the amount of flavonoids in walnut leaves by extracting raw materials with organic solvents followed by sample preparation and determining the optical density by differential spectrophotometry is the single extraction of raw materials. Ethyl alcohol is used as a solvent extraction agent at a concentration of 80% in the ratio of raw materials: solvent extraction agent 1:30. Extraction time is extraction in a boiling water bath for 30 minutes. The degree of grinding of raw materials is 2 mm. Aluminum chloride is added to the extraction for the complexation reaction for 40 minutes. The quantifying the amount of flavonoids in walnut leaves is carried out at a wavelength of 412 nm in terms of rutin. The content of the amount of flavonoids, X as a percentage, in terms of rutin and absolutely dry raw materials is calculated by the formula. In the absence of a standard sample of rutin, it is advisable to use the theoretical value of the specific absorption index at 412 nm - 240:.EFFECT: method allows quantifying the amount of flavonoids in the walnut leaves in terms of rutin.1 cl, 3 dwg, 3 tbl, 2 ex
BACKGROUND: Arsenic (ARS) is a toxic heavy metal that poses a significant concern for both animal and human health.
AIM: The study investigated the ameliorative effect of myricetin (MRC) against arsenic-induced immune dysfunction, oxidative stress, hematological changes, hepatic and renal injuries, and inflammatory gene expression in rats.
METHODS: Rats were divided into 4 groups: the control group (CON) received orally administered distilled water (1 ml/rat), and the ARS group received 10 mg/kg orally, the MRC group received 5 mg of MRC/kg orally, and the co-treated group (ARS+MRC) received 10 mg/kg of ARS and 5 mg/kg b.w. of MRC orally.
RESULTS: The results showed that co-treatment of ARS-exposed rats with MRC significantly corrected erythrocyte parameters (except MCV) and leukocyte parameters (except basophils; p < 0.05). Furthermore, the ARS group significantly reduced total proteins and globulins while significantly increasing liver functions and uric acid levels (p < 0.05). Co-administration with MRC significantly mitigated the heart indices (gamma-glutamyl transferase, creatine phosphokinase, CK, lactate dehydrogenase) and lipid dysfunction caused by ARS exposure (p < 0.05). In ARS-exposed rats, there was a significant reduction in antioxidant enzymes and immunoglobulins (IgG and IgM), as well as significantly increased oxidative stress (p < 0.05). The MRC treatment effectively restored the redox status and immune variables that were disrupted by ARS exposure. Serum levels of nitric acid and lysosome were significantly lower, while levels of IL-4, TNF-α, and IFN-γ were higher in the ARS group compared to the other groups (p < 0.05). Immunohistopathology revealed that the expression of Cox2 in kidney and liver tissues varied from mild to moderate in the ARS+MRC group. Furthermore, the ARS-induced upregulation of mRNA levels of inflammatory genes such as IFN-γ, TNF-α, IL-10, and IL-6 in hepatic tissues and MRC significantly attenuated this elevation. These findings suggest that ARS has detrimental effects on blood hematology and health, triggering specific inflammatory genes and indicating the genotoxicity of ARS. However, co-treatment with MYC can mitigate these negative effects.
CONCLUSION: MRC exhibits a significant protective effect against ARS due to its anti-inflammatory and antioxidant properties.
Sepsis is a dysregulated systemic immune response to infection i.e. responsible for ∼35% of in-hospital deaths at a significant fiscal healthcare cost. Our laboratory, among others, has demonstrated the efficacy of targeting negative checkpoint regulators (NCRs) to improve survival in a murine model of sepsis, cecal ligation and puncture (CLP). B7-CD28 superfamily member, V-domain immunoglobulin suppressor of T cell activation (VISTA), is an ideal candidate for strategic targeting in sepsis. VISTA is a 35 to 45 kDa type 1 transmembrane protein with unique biology that sets it apart from all other NCRs. We recently reported that VISTA-/- mice had a significant survival deficit post-CLP, which was rescued upon adoptive transfer of a VISTA-expressing pMSCV-mouse Foxp3-EF1α-GFP-T2A-puro stable Jurkat cell line (Jurkatfoxp3 T cells). Based on our prior study, we investigated the effector cell target of Jurkatfoxp3 T cells in VISTA-/- mice. γδ T cells are a powerful lymphoid subpopulation that require regulatory fine-tuning by regulatory T cells to prevent overt inflammation/pathology. In this study, we hypothesized that Jurkatfoxp3 T cells nonredundantly modulate the γδ T cell population post-CLP. We found that VISTA-/- mice have an increased accumulation of intestinal CD69low γδ T cells, which are not protective in murine sepsis. Adoptive transfer of Jurkatfoxp3 T cells decreased the intestinal γδ T cell population, suppressed proliferation, skewed remaining γδ T cells toward a CD69high phenotype, and increased soluble CD40L in VISTA-/- mice post-CLP. These results support a potential regulatory mechanism by which VISTA skews intestinal γδ T cell lineage representation in murine sepsis.
Some studies suggest an association between iron overload and cardiovascular diseases (CVDs). However, the relationship between dietary iron intake and atrial fibrillation (AF) remains uncertain, as does the role of genetic loci on this association. The study involved 179,565 participants from UK Biobank, tracking incident atrial fibrillation (AF) cases. Iron intake was categorized into low, moderate, and high groups based on dietary surveys conducted from 2009 to 2012. The Cox regression model was used to estimate the risk of AF in relation to iron intake, assessing the hazard ratio (HR) and 95% confidence interval (95% CI). It also examined the impact of 165 AF-related and 20 iron-related genetic variants on this association. Pathway enrichment analyses were performed using Metascape and FUMA. During a median follow-up period of 11.6 years, 6693 (3.97%) incident AF cases were recorded. A total of 35,874 (20.0%) participants had high iron intake. High iron intake was associated with increased risk of AF [HR: 1.13 (95% CI: 1.05, 1.22)] in a fully adjusted model. Importantly, there were 83 SNPs (11 iron-related SNPs) that could enhance the observed associations. These genes are mainly involved in cardiac development and cell signal transduction pathways. High dietary iron intake increases the risk of atrial fibrillation, especially when iron intake exceeds 16.95 mg. The association was particularly significant among the 83 SNPs associated with AF and iron, the individuals with these risk genes. Gene enrichment analysis revealed that these genes are significantly involved in cardiac development and cell signal transduction processes.
The invention provides a traditional Chinese medicine formula for treating chronic pharyngitis, belonging to the technical field of treatment of chronic pharyngitis by Chinese herbal medicines; the medicament is prepared from the following raw materials: 15g of burdock, 15g of fructus forsythiae, 10g of semen oroxyli, 15g of blackberry lily, 15g of liquorice, 30g of radix scrophulariae, 15g of radix trichosanthis, 20g of radix ophiopogonis, 15g of platycodon grandiflorum, 15g of arisaema cum bile, 15g of codonopsis pilosula, 15g of schisandra chinensis, 12g of turmeric and 10g of myrobalan. The traditional Chinese medicine formula for treating chronic pharyngitis has the effects of dispelling wind and clearing heat, tonifying qi and yin, promoting the production of body fluid, detoxifying, reducing phlegm and relieving sore throat. Combines strict prescription of pathogenesis and has definite clinical curative effect. The traditional Chinese medicine formula for treating chronic pharyngitis can be prepared into various dosage forms and is convenient to take. The traditional Chinese medicine formula for treating chronic pharyngitis is safe to use, has no toxic or side effect, and can be used for treating various acute and chronic pharyngolaryngitis. The traditional Chinese medicine formula for treating chronic pharyngitis is short in taking course and low in cost, and can reduce the economic stress of a user.
NEW MATERIAL:The esterified product of sterol and lactic acid or carboxylic acid obtained by the intermolecular oligoesterification of lactic acid of formula (n is 0 or integer of >=1). EXAMPLE:Cholesteryl lactate. USE:Raw material of cosmetics and external remedy. PROCESS:For example, lactic acid or a carboxylic acid of formula obtained by the intermolecular oligoesterification of lactic acid is charged together with a sterol (e.g. cholesterol) in a reactor, mixed with tin chloride, etc. as a catalyst and toluene, etc. as a refluxing solvent, and reacted by heating at 140-220 deg.C under thorough agitation. After the completion of the reaction, the catalyst is removed by filtration, and the filtrate is decolorized with activated clay, etc. and deodorized by blasting steam at 150-220 deg.C under reduced pressure to obtain esterified product. Cosmetics such as cold cream, etc. can be prepared by mixing the ester with liquid praffin, white vaseline, beeswax, water, perfume, etc.
BACKGROUND: Peroxiredoxin 2 (Prx2), an intracellular protein that regulates redox reactions, released from red blood cells is involved in inflammatory brain injury after intracerebral hemorrhage (ICH). Toll-like receptor 4 (TLR4) may be crucial in this process. This study investigated the role of the Prx2-TLR4 inflammatory axis in brain injury following experimental ICH in mice.
METHODS: First, C57BL/6 mice received an intracaudate injection of autologous arterial blood or saline and their brains were harvested on day 1 to measure Prx2 levels. Second, mice received an intracaudate injection of either recombinant mouse Prx2 or saline. Third, the mice were co-injected with autologous arterial blood and conoidin A, a Prx2 inhibitor, or vehicle. Fourth, the mice received a Prx2 injection and were treated with TAK-242, a TLR4 antagonist, or saline (intraperitoneally). Behavioral tests, magnetic resonance imaging, western blot, immunohistochemistry/immunofluorescence staining, and RNA sequencing (RNA-seq) were performed.
RESULTS: Brain Prx2 levels were elevated after autologous arterial blood injection. Intracaudate injection of Prx2 caused brain swelling, microglial activation, neutrophil infiltration, neuronal death, and neurological deficits. Co-injection of conoidin A attenuated autologous arterial blood-induced brain injury. TLR4 was expressed on the surface of microglia/macrophages and neutrophils and participated in Prx2-induced inflammation. TAK-242 treatment attenuated Prx2-induced inflammation and neurological deficits.
CONCLUSIONS: Prx2 can cause brain injury following ICH through the TLR4 pathway, revealing the Prx2-TLR4 inflammatory axis as a potential therapeutic target.
Pharmaceutical compositions useful in the treatment of mental diseases comprise a diluent or carrier and 1-(1,2-diphenylethyl)-pyrrolidine or a pharmacologically acceptable acid addition salt thereof e.g. the hydrochloride, sulphate, nitrate, phosphate, citrate, acetate, lactate or succinate.  The compositions may be in unit dosage forms suitable for oral or parenteral administration e.g. a tablet, capsule, pill, powder packet, granule, wafer, cachet, aqueous solution, aqueous or oil suspension, emulsion or elixir and forms allowing prolonged or delayed action e.g. laminated and enterically coated tablets, such forms comprising conventional diluents, carriers, dispersing or suspending agents and preservatives.  As optional additional active ingredients there may be present sedatives e.g. barbital, phenobarbital, pentobarbital mephobarbital, amobarbital, secobarbital and hexobarbital, ataractics e.g. meprobamate, promazine, chlorpromazine, azacyclonol and phenaglycolol, hormones e.g. stilbestrol, diethylstilbestrol testosterone and methyltestosterone and vitamins.
Participants will receive 3% acetic acid topical application at cervical lesion and transformation zone. Application of 3% acetic acid will be guided by colposcopy using a small cotton-tipped applicators and wooden end of the applicators.
According to the initial treatment plan of the patients, the patients were divided into R-CHOP and R-chemo groups. Both groups received zanubrutinib 160 mg bid p.o. d1-28 maintenance treatment for 12 months after induction and consolidation therapy reached the maximum efficacy.
PURPOSE: The aim of this study was to characterize a second-generation wide-detector dual-layer spectral computed tomography (CT) system for material quantification accuracy, acquisition parameter and patient size dependencies, and tissue characterization capabilities.
METHODS: A phantom with multiple tissue-mimicking and material-specific inserts was scanned with a dual-layer spectral detector CT using different tube voltages, collimation widths, radiation dose levels, and size configurations. Accuracy of iodine density maps and virtual monoenergetic images (MonoE) were investigated. Additionally, differences between conventional and MonoE 70 keV images were calculated to evaluate acquisition parameter and patient size dependencies. To demonstrate material quantification and differentiation, liver-mimicking inserts with adipose and iron were analyzed with a two-base decomposition utilizing MonoE 50 and 150 keV, and root mean square error (RMSE) for adipose and iron content was reported.
RESULTS: Measured inserts exhibited quantitative accuracy across a wide range of MonoE levels. MonoE 70 keV images demonstrated reduced dependence compared to conventional images for phantom size (1 vs. 27 HU) and acquisition parameters, particularly tube voltage (4 vs. 37 HU). Iodine density quantification was successful with errors ranging from -0.58 to 0.44 mg/mL. Similarly, inserts with different amounts of adipose and iron were differentiated, and the small deviation in values within inserts corresponded to a RMSE of 3.49 ± 1.76% and 1.67 ± 0.84 mg/mL for adipose and iron content, respectively.
CONCLUSION: The second-generation dual-layer CT enables acquisition of quantitatively accurate spectral data without compromises from differences in patient size and acquisition parameters.
The procedure is performed on a similar fashion until atrial septal entry. Once the atrial wall is traversed, and the Mullins sheath is within the left atrium, the mitral valve is crossed with a flexible 0.032- or 0.035 in- 145 cm J-tipped wire. This step could be assisted by a steerable sheath. Once the mitral valve is crossed, the initial wire will be exchanged with a looped stiff wire (Safari or similar) to the left ventricle by use of a 5/6 f pigtail catheter. A commercially available balloon is used to perform the valvulotomy/commissurotomy procedure. Choice of balloon size is made following the formula: Balloon size = patient height (cm)/10 + 10. Fine tuning of the balloon size will be performed peri-operative based on transesophageal echo findings. Use of a separate stiff wire placed in the left atrium/pulmonary vein to ease passage through the atrial septum is left to the discretion of the operator based on the anatomical challenges faced during the procedure.
This study aims to explore the risk factors for carotid plaque (CP) and carotid common artery intima-media thickening (CCAIMT) and clarify the relationship between the risk factors with the number of CPs and the side of CCAIMT in a high-stroke-risk population in Qujing, Yunnan, China. Carotid ultrasonography was performed in 430 participants with high stroke risk, who were divided into different groups according to their ultrasound results. The risk factors and blood biochemical indices were recorded for assessment. The prevalence rates of CP and CCAIMT were 88.1% and 70.5%, respectively. Multivariate logistic regression analysis identified age and lack of physical exercise as risk factors of CP. Compared to participants without CP, participants who performed little physical exercise were prone to have one CP, while participants with risk factors for smoking, older age, and physical inactivity were more likely to have several CPs. Risk factors for CCAIMT were older age, male, and the levels of low density lipoprotein cholesterol. Risk factors for left CCAIMT included a history of hyperlipidemia and low density lipoprotein cholesterol, while male sex was the sole risk factor for right CCAIMT. Finally, male sex and advanced age were identified as risk factors for dual CCAIMT. The research reveals the risk factors for CP and CCAIMT, also clarifies the relationship between the risk factors, CP numbers, and the side of CCAIMT.
Part 1: From Day 1 until Day 12 the dose 1 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 1 of BAY1902607 will be given only once.